MedPath
Found 15 clinical trials|View Analysis
Sort by:

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Phase 2
Recruiting
Conditions
Therapy-Related Myelodysplastic Syndrome
Secondary Myelodysplastic Syndrome
Interventions
Drug: Azacitidine
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Venetoclax
First Posted Date
2022-05-18
Last Posted Date
2024-05-22
Lead Sponsor
Uma Borate
Target Recruit Count
53
Registration Number
NCT05379166
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Oregon Health & Science University, Portland, Oregon, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Phase 3
Active, not recruiting
Conditions
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoid Leukemia
Therapy-Related Myelodysplastic Syndrome
Mixed Phenotype Acute Leukemia
Undifferentiated Leukemia
Acute Leukemia
Interventions
Biological: Orca-T
Biological: Standard-of-Care
First Posted Date
2022-04-07
Last Posted Date
2024-05-28
Lead Sponsor
Orca Biosystems, Inc.
Target Recruit Count
174
Registration Number
NCT05316701
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

University of Michigan Health System - Michigan Medicine, Ann Arbor, Michigan, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 16 locations

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Phase 1
Recruiting
Conditions
Myelodysplastic Syndromes, Secondary
Myelodysplastic Syndromes, Previously Treated
Treatment-Related Acute Myeloid Leukemia
Therapy-Related Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia With Failed Remission
Myelodysplastic Syndromes, de Novo
Lymphoblastic Lymphoma, in Relapse
Acute Leukemia of Ambiguous Lineage in Relapse
Lymphoblastic Lymphoma, Refractory
Acute Leukemia of Ambiguous Lineage
Interventions
First Posted Date
2022-03-23
Last Posted Date
2024-04-02
Lead Sponsor
Andrew E. Place, MD
Target Recruit Count
92
Registration Number
NCT05292664
Locations
🇺🇸

University of California San Francisco-Benioff Children's Hospital, San Francisco, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Phase 1
Active, not recruiting
Conditions
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic Syndrome
Therapy-Related Myelodysplastic Syndrome
Interventions
First Posted Date
2020-09-16
Last Posted Date
2024-11-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
34
Registration Number
NCT04550442
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Phase 1
Recruiting
Conditions
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome
Recurrent Myelodysplastic Syndrome
Therapy-Related Myelodysplastic Syndrome
Refractory Myelodysplastic Syndrome
Interventions
First Posted Date
2019-11-12
Last Posted Date
2024-12-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
116
Registration Number
NCT04160052
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

SRSF2 Gene Mutation in Patients With t-MDS/AML

Completed
Conditions
Therapy Related Myelodysplastic Syndrome and Therapy Related Acute Myeloid Leukemia
Interventions
Diagnostic Test: PCR and cytogenetics
First Posted Date
2019-03-29
Last Posted Date
2020-05-19
Lead Sponsor
Zeinab Albadry Mohammed Zahran
Target Recruit Count
139
Registration Number
NCT03894852
Locations
🇪🇬

Assiut, Assiut, Egypt

🇪🇬

Zeinab Albadry Mohammed Zahran, Assiut, Egypt

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Phase 1
Completed
Conditions
Previously Treated Myelodysplastic Syndrome
Refractory High Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
Secondary Myelodysplastic Syndrome
Therapy-Related Myelodysplastic Syndrome
Interventions
First Posted Date
2017-12-02
Last Posted Date
2021-10-19
Lead Sponsor
Brian Jonas
Target Recruit Count
4
Registration Number
NCT03359460
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Early Phase 1
Terminated
Conditions
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia in Remission
Hematopoietic Cell Transplantation Recipient
Non-Hodgkin Lymphoma
Plasma Cell Myeloma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Minimal Residual Disease
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hematologic Malignancy
Interventions
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Irradiated Allogeneic Cells
First Posted Date
2017-09-05
Last Posted Date
2023-06-26
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
2
Registration Number
NCT03272633
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Phase 2
Completed
Conditions
Acute Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Langerhans Cell Histiocytosis
Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Non-Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
Therapy-Related Myelodysplastic Syndrome
Acute Myeloid Leukemia
Interventions
Biological: Anti-Thymocyte Globulin
Drug: Busulfan
Drug: Clofarabine
Drug: Cyclophosphamide
Biological: Filgrastim-sndz
Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Rituximab
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
First Posted Date
2017-03-30
Last Posted Date
2023-10-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
6
Registration Number
NCT03096782
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1
Completed
Conditions
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Aplastic Anemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Chronic Myelomonocytic Leukemia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Lymphoblastic Lymphoma
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Interventions
Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Rituximab
Drug: Tacrolimus
Radiation: Total-Body Irradiation
First Posted Date
2016-11-09
Last Posted Date
2023-02-16
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
11
Registration Number
NCT02960646
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath